Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults
Status:
Completed
Trial end date:
2021-02-02
Target enrollment:
Participant gender:
Summary
The purpose of this is study is to compare the efficacy of BHV-3000 (rimegepant) to placebo
as a preventive treatment for migraine, as measured by the reduction in the number of
migraine days per month.